在局部晚期直肠癌中,在全新辅助疗法和标准新辅助化学放射治疗后的多模式评估准确地预测了完全响应者
Emre Özoran1, İbrahim Halil Özata2, Derya Salim Uymaz2
1Department of General Surgery, Koç University School of Medicine, Istanbul, Turkey. eozoran@ku.edu.tr.
International journal of colorectal disease
|September 14, 2023
概括
在直肠癌患者中,全新辅助疗法 (TNT) 与标准化疗放射治疗 (SNCRT) 相比,显示出更高的完全响应率. 然而,这并没有导致在本研究中改善生存结果.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 手术瘤学手术瘤学
背景情况:
- 局部晚期直肠癌 (LARC) 需要有效的新辅助治疗策略来改善结果.
- 总的新辅助疗法 (TNT) 是一种不断发展的方法,旨在提高手术前治疗的疗效.
- 标准的新辅助化学放射治疗 (SNCRT) 仍然是LARC的常见治疗方式.
研究的目的:
- 在严格选择的LARC患者中比较TNT和SNCRT之间的局部再生率.
- 评估二次结果,包括4年无病生存率 (DFS) 和整体生存率 (OS).
- 评估多模式评估在识别全响应者后新辅助疗法的有效性.
主要方法:
- 在2014年1月至2021年1月期间接受治疗的LARC患者的回顾性分析.
- 用数字直肠检查,内镜和MRI评估患者的完整反应.
- 系统性评估包括腹部上部MRI和胸部CT.
主要成果:
- 与SNCRT (20.0%) 相比,在TNT组 (45.4%) 观察到更高的累积完全响应率 (p < 0.0001).
- 在TNT (10.8%) 和SNCRT (23.1%) (p = 0.357) 之间,本地复生率没有显著差异.
- 在两组治疗中,病理结局和4年DFS和OS率在两组治疗中是可比的.
结论:
- 多模式评估有效地识别了TNT后的完整响应者,导致局部复发率低.
- 与SNCRT相比,TNT显示累积完整反应率增加.
- 尽管反应率有所提高,但TNT在这个LARC队列中并没有转化为显著的生存优势.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
5.7K
相关概念视频
Assessment of the Rectum and Anus
268
Evaluating the rectum and anus plays a crucial role in conducting a thorough physical examination of the gastrointestinal system. Although it may be uncomfortable and often embarrassing for the patient, it holds immense diagnostic value, particularly in detecting gastrointestinal diseases and abnormalities. This guide will explain how to perform this assessment using inspection and palpation methods.
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
268
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
